choong ang vaccine laboratories co., ltd

Choong Ang Vaccine Laboratories Co., Ltd.

1476-37 Yuseong-daero, Yuseong-gu, Deajeon, Republic of KoreaTelephone_ +82-42-863-9322

www.cavaclab.com

Choong Ang Vaccine Laboratories Co., Ltd.

Chong Ang Vaccine Laboratories Co., Ltd.

1476-37 Yuseong-daero, Yuseong-gu, Deajeon, Republic of KoreaTelephone_ +82-42-870-0545

www.cavaclab.com

Choong Ang Vaccine Laboratories C

o., Ltd.

History for half a century,Front runner in the animal vaccine industry

Since established in 1968, Choong Ang Vaccine Laboratories Co., Ltd. (CAVAC) is an animal vaccine manufacturer which has pioneered the vaccine business and contributed to the rich lives of animals and humans by providing products and services beloved and trusted by customers.

In order to be the top tier in every business section, CAVAC is taking the lead in advancing the vaccine market in domestic and abroad by focusing on developing and training manufacturing-based technology, production management, human resources, investing R&D technology, empowering marketing, etc.

As a leading vaccine research/manufacturing company in the animal vaccine industry for half a century, CAVAC will always be with you for solutions that drives your business more insightful.

2019 Winning an award for the export of 10 million US dollars

2018 First Korean company of WHO GMP approval

2016 Egypt Governmental Audit

2013 Passed Bayer HealthCare audit

2009 Selected as one of Asia’s 200 Best Under A Billion companies by Forbes

2003 Listed in Korean Securities Dealers Automated Quotation (KOSDAQ)

1994 First Korean company of Korea Veterinary Good Manufacturing Practice (GMP) approval

1993 First Korean company of exporting its vaccines to the foreign countries (Thailand, Pakistan)

1968 Established Choong Ang Livestock Infectious Disease Laboratory

Your future is bright with CAVACCompany History

3Global Bio Leader - CAVAC

Innovative brandfor the best quality vaccine

CAVAC has developed and improved the quality of Korean vaccines on a par with the products of the world’s top companies.

CAVAC is always pursuing the perfection of animal disease prevention and management services by providing the nation’s best professional veterinary diagnostic service and technical support to farmers along with vaccines.

www.cavaclab.com Global Bio Leader - CAVAC4 5

Product list

Global Bio Leader - CAVAC 7

POULTRY VACCINES

Killed vaccines

Flu H9 ME+ND7 AIV (ME strain)+recombinant NDV (genotype VII) combined inactivated vaccine

500ml

Flu H9N2+ND AIV+NDV combined inactivated vaccineAvian influenza virus (AIV, H9N2) Newcastle disease virus (NDV, LaSota strain)

≥ 109.5EID50

≥ 109.5EID50

500ml

ND-7Recombinant NDV (genotype VII) inactivated vaccineNewcastle disease virus (NDV, rNDV-mF strain) ≥ 108.0EID50

500ml

Live vaccines

QX-IBQX type IBV live vaccine Infectious bronchitis virus (IBV, K40/09 HP strain) ≥ 102.5EID50

2,000 doses

QX-CastleIBV (QX type)+NDV combined live vaccine for day old chick at hatcheryInfectious bronchitis virus (IBV, K40/09 HP strain)Newcastle disease virus (NDV, NDRL0901 strain)

≥ 106.0EID50

≥ 102.5EID50

2,000 doses

IB-CastleIBV+NDV combined live vaccine for day old chick at hatcheryInfectious bronchitis virus (IBV, AVR1/08 strain) Newcastle disease virus (NDV, NDRL0901 strain)

≥ 102.5EID50

≥ 106.0EID50

2,000 doses

B1+IBNDV (B1)+IBV (H120) combined live vaccineNewcastle disease virus (NDV, B1 strain) Infectious bronchitis virus (IBV, H120 strain)

≥ 106.0EID50

≥ 102.5EID50

2,000 doses

LaSota+IBNDV (LaSota)+IBV (H120) combined live vaccineNewcastle disease virus (NDV, LaSota strain) Infectious bronchitis virus (IBV, H120 strain)

≥ 106.0EID50

≥ 102.5EID50

2,000 doses

LaSotaNDV (LaSota) live vaccineNewcastle disease virus (NDV, LaSota strain) ≥ 106.0EID50

2,000 doses

ND-0901NDV live vaccineNewcastle disease virus (NDV, NDRL0901 strain) ≥ 106.0EID50

2,000 doses

IBD Win+ IBDV live vaccine (Intermediate plus)Infectious bursal disease virus (IBDV, Winterfield 2512 strain) ≥ 102.0EID50

2,000 doses

GumboroIBDV live vaccine (Intermediate)Infectious bursal disease virus (IBDV, LZD 228-JAC3 strain) ≥ 102.0TCID50

2,000 doses

S/9RSalmonella Gallinarum (9R) live vaccineSalmonella Gallinarum (SG, 9R strain) ≥ 2×107.0CFU

1,000 doses

MG-FMycoplasma gallisepticum (F) live vaccineMycoplasma gallisepticum (MG, F810 strain) ≥ 1×105.0CCU

1,000 doses

Product list Vaccination program

Killed vaccines

Qx ND-7

IBV (QX type)+recombinant NDV (genotype VII) combined inactivated vaccineInfectious bronchitis virus (IBV, ADL05258 strain)Newcastle disease virus (NDV, rNDV-mF strain)

≥ 106.0EID50

≥ 108.0EID50

500ml

Qx Flu-4

IBV (KM91, QX type)+NDV+AIV combined inactivated vaccineInfectious bronchitis virus (IBV, KM91 strain) Infectious bronchitis virus (IBV, ADL05258 strain) Newcastle disease virus (NDV, LaSota strain) Avian influenza virus (AIV, H9N2)

≥ 106.0EID50

≥ 106.0EID50

≥ 108.0EID50

≥ 108.0EID50

1,000 doses

Qx Flu-5

IBV (KM91, QX type)+NDV+EDSV+AIV combined inactivated vaccineInfectious bronchitis virus (IBV, KM91 strain) Infectious bronchitis virus (IBV, ADL05258 strain)Newcastle disease virus (NDV, LaSota strain) Egg drop syndrome virus (EDSV, K11 strain) Avian influenza virus (AIV, H9N2)

≥ 106.0EID50

≥ 106.0EID50

≥ 108.0EID50

≥ 105.5EID50

≥ 108.0EID50

1,000 doses

3BN

IBV (M41, KM91, QX type)+NDV combined inactivated vaccineInfectious bronchitis virus (IBV, M41 strain) Infectious bronchitis virus (IBV, KM91 strain) Infectious bronchitis virus (IBV, ADL05258 strain)Newcastle disease virus (NDV, LaSota strain)

≥ 105.6EID50

≥ 106.3EID50

≥ 106.3EID50

≥ 108.2EID50

1,000 doses

ING-Plus

IBV (M41, KM91)+NDV+IBDV combined inactivated vaccineInfectious bronchitis virus (IBV, M41 strain) Infectious bronchitis virus (IBV, KM91 strain) Newcastle disease virus (NDV, LaSota strain) Infectious bursal disease virus (IBDV, CAG strain)

≥ 105.8EID50

≥ 106.1EID50

≥ 108.4EID50

≥ 106.4TCID50

1,000 doses

BNE

IBV (M41)+NDV+EDSV combined inactivated vaccineInfectious bronchitis virus (IBV, M41 strain) Newcastle disease virus (NDV, LaSota strain) Egg drop syndrome virus (EDSV, K11 strain)

≥ 105.9EID50

≥ 108.4EID50

≥ 107.7EID50

1,000 doses

Coryza-PlusInfectious coryza inactivated vaccineAvibacterium paragallinarum serotype A Avibacterium paragallinarum serotype C

≥ 108.0CFU≥ 108.0CFU

1,000 doses

AdenoFowl adenovirus inactivated vaccineFowl adenovirus type 4 (FAdV-4, K4 strain) ≥ 107.0TCID50

1,000 doses

Autogenous vaccine Avian E.coli inactivated vaccine 1,000 doses

※ It is optional to use IBD vaccine according to the level of the maternally derived antibody and history of the chicken flock.

IB-Castle

22 days

Gumboro or

IBD Win+

24 days

MG-F

35 days

Adeno

21 days

IB-Castle

12 days

ING-Plus or

3BN

7 days

IB-Castle

One day

Gumboro or

IBD Win+

16 days

AE

85 days

AEP

75 days

QX Flu-4

60 days

S/9R

42 days

E. coliCoryza

90 days

Qx Flu-5

100 days

S/9R

110 days

IB-Castle

95 days

Layer

IB-Castleor

QX-Castle

One day

QX-IB

10 days

Gumboro or

IBD Win+ ND-0901

12 days

Broiler

※ Regular vaccination of IB-Castle at intervals of 1~2 month after starting egg-laying

BreederGumboro

orIBD Win+

24 days

MG-F

35 days

IB-Castle

50 days

IB-Castle

22 days

IB-Castle

12 days

ING-Plus or

3BN

7 days

IB-Castle

One day

Gumboro or

IBD Win+

16 days

Adeno

100 days

IB-Castle

105 days

E. coliCoryza

115 days

ING-Plus

125 days

Qx Flu-5

90 days

AEP

75 days

QX Flu-4

60 days

AE

80 days

Poultry Vaccines Global Bio Leader - CAVAC8 9

IB-Castleor

QX-Castle

One day

ING-Plus or

3BN

7 days

QX-IB

10 days

Gumboro or

IBD Win+

14 days

IB-Castle

20 days

Gumboro or

IBD Win+

24 days

QX-Castle

40 daysNative chicken

PoulShot® IB-Castle PoulShot® ND-0901 PoulShot® IB-Castle PoulShot® ND-0901

PoulShot® IB-Castle protects against respiratory and nepropathogeinc IBV

Ciliostasis between K-I IBV challenged groups

NDV (NDRL0901): The latest isolate, respiratory and enterotrophic virusIBV (AVR1/08): Strong immunity induction of respiratory system

KJW, Kr005: Korean pathogenic strain / Herts 33: International standard pathogenic strainMY3519: Malaysian pathogenic strain / VN5/2007: Vietnamese pathogenic strain

Ciliostasis between QX-IBV challenged groups

Indication An aid in the control and prevention of Newcastle disease and infectious bronchitis caused by NDV and IBV

Composition and quantity

Infectious bronchitis virus (IBV, AVR1/08 strain) Newcastle disease virus (NDV, NDRL0901 strain)

≥ 102.5EID50

≥ 106.0EID50

Administration and dosage

-1st Administer by spray: 1day of age-2nd Administer by spray or drinking water: at least 5 days of age

Indication An aid in the control and prevention of Newcastle disease caused by NDV

Composition and quantity Newcastle disease virus (NDV, NDRL0901 strain) ≥ 106.0EID50

Administration and dosage Spray, Drinking water, Eye drop

LIVE

LIV

E

GroupNo. of chicks

Vaccination Challenge

Age Vaccine Route Strain

G1 8 1dayPoulShot® IB-Castle

SprayAVR1/08 Parental strain

G2 8 1day K40/09 CE4

G3 10 1day - - AVR1/08 Parental strain

G4 10 1day - - K40/09 CE4


Group Vaccination/Challenge

100%

90%

80%

70%

60%

50%

40%

30%

20%

10%

0%

8

7

6

5

4

3

2

1

0Vaccinated group Challenge control Non-vaccinated control

Protectio

n rate

Virus titer in bursa(EID50/ml)

Avg of B:B ratio

Protection rate

100% 100%

20%

3.33 3.33

1.96

4.2

7.06

100%

95%

90%

85%

80%

75%

70%

65%

60%

55%

50%

5

4.5

4

3.5

3

2.5

2

1.5

1

0.5

0

Protection rate HI titer (log2)

KJW Herts33 Kr005 MY3519 VN5/2007

Pro

tect

ion

rat

e HI titer (lo

g2)

High defense against various pathogenic NDV

Sco

re

Sco

re

G1 upper

G3 upper

G1 middle

G3 middle

G1 lower

G3 lower

4

3

2

1

0G2

upperG4

upperG2

middleG4

middleG2

lowerG4

lower

4

3

2

1

0

CT

valu

e in

vert

edGroup Vaccination/Challenge

G1 Vacc/K-I C G3- / K-I C G2 Vacc/QX C G4- / QX C

0

10

20

30

40

50

CT

valu

e in

vert

ed



0

10

20

30

40

50

Sco

re

Sco

re

G1 upper

G3 upper

G1 middle

G3 middle

G1 lower

G3 lower

4

3

2

1

0G2

upperG4

upperG2

middleG4

middleG2

lowerG4

lower

4

3

2

1

0

CT

valu

e in

vert

ed



0

10

20

30

40

50

CT

valu

e in

vert

ed



0

10

20

30

40

50

Group Tracheal position

Group Tracheal position


PoulShot® Gumboro PoulShot® IBD Win+

PoulShot® IBD Win+ shows great protection and safety in chicks

Since commercial chicks possessed maternally-derived antibody prior to vaccination, they did not show 100% seroconversion one week after vaccinationB:B ratio: Bursa weight(g)/Body weight(g)x1,000, If the B:B ratio has increased, it means that protection was not enough.

DPV: Days post vaccination DPC: Days post challenge

Indication An aid in the control and prevention of infectious bursal disease caused by IBDV

Composition and quantity Infectious bursal disease virus (IBDV, LZD 228-JAC3 strain) ≥ 102.0TCID50


Vaccinate by drinking water.

Age Water 1 day 2L

10 days 20L40 days 80L

Indication An aid in the control and prevention of infectious bursal disease caused by IBDV

Composition and quantity Infectious bursal disease virus (IBDV, Winterfield 2512 strain) ≥102.0EID50


Vaccinate by drinking water.For broilers, vaccinate between 7 and 14 days of age.For layers and breeders, vaccinate between 10~14 days of age, and as a supplement, vaccinate between 10~12 weeks of age.

LIVE

LIV

E

Group0 DPV 0 DPC 10 DPC

MortalitySN titer (GMT) AGID SN titer (GMT) AGID SN titer (GMT) AGID

Vaccinated/Challenged 1.2 0% 2,702 100% 2,964 100% 0%

Vaccinated-only 1.3 0% 2,580 100% 2,048 100% 0%

Challenged-only 1.3 0% 1 0% 3,251 100% 76%

Control 1.3 0% 1 0% 1 0% 0%

100%

90%

80%

70%

60%

50%

40%

30%

20%

10%

0%

3,500

3,000

2,500

2,000

1,500

1,000

500

-0 WPV 1 WPV 2 WPV

100% 100% 100%

80%

10%

0% 0% 0%

3 WPV Vaccinated Control

891

208

1,663

3,104

37141

676

9

AG

ID p

osi

tive

rat

e

SN t

iter

(G

MT)

Vaccinated Control 0 WPV 1 WPV 2 WPV 3 WPV

PoulShot® Gumboro shows perfect protection against very Virulent IBDV challenge

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

0

1

2

3

4

5

6

7

8

Protectio

n rate

3.3 3.33

100%

Vaccinated/Challenged

7.06

1.9620%

Challenged-only

4.2

100%

Control

Virus titer in bursa (EID50/ml) B:B ratio on average Protection rateWPV: Weeks post vaccination WPV: Weeks post vaccination


PoulShot® MG-F PoulShot® S/9R

Increase in Egg Production and Egg QualityQuick Onset of Immunity and incredible Protection

against virulent strain

In the microplate agglutination test, Salmonella Gallinarum (SG, 9R strain) is uesd as an antigen

* Not applicable, there is no death.** Chickens in control group survived an average of 7.8 days after challenge with virulent strain.

Indication An aid in the control and prevention of avian mycoplasmosis caused by Mycoplasma gallisepticum

Composition and quantity Mycoplasma gallisepticum (MG, F810 strain) ≥ 1×105.0CCU


Reconstitute the vaccine with the enclosed diluent and administer one eye drop- 1st vaccination: 6 weeks of age- 2nd vaccination: 3 weeks after 1st vaccination

Indication An aid in the control and prevention of fowl typhoid caused by Salmonella Gallinarum

Composition and quantity Salmonella Gallinarum (SG, 9R strain) ≥ 2x107.0CFU


Administer 0.2ml subcutaneously in the neck after dissolving the vaccine in the diluent.-1st vaccination: 6~8 weeks of age-2nd vaccination: at 12 weeks of after the first vaccination

LIVE

LIV

E

Group Mortality

Re-isolation rate

Dead Alive

Liver Spleen Liver Spleen

PoulShot® S/9R 0% NA* NA 0% 0%

Vaccine N 0% NA NA 0% 0%

Control 93.3%** 100% 100% 100% 100%

F strain 6/85 ts-11 Bacterin

Form Lyophilized Lyophilized Frozen Emulsion

Administration Eye drop Spray Eye drop IM, SC

Vaccination age (week) 1st: 6 weeks, 2nd: 9 weeks ≥ 6 weeks 6~24 weeks (at least 2 weeks) < 16 weeks

Persistence in the tracheal epithelium Excellent Good Good No

Serological monitoring Very good Slight (almost negative) Moderate (about 50% positive) Very good

Field strain replacement Excellent Unknown Good No

100%

90%

80%

70%

60%

50%

40%

30%

20%

10%

0%

3,500

3,000

2,500

2,000

1,500

1,000

500

-0 WPV

WPV: Weeks post vaccination WPV: Weeks post vaccination

1 WPV 2 WPV

100% 100% 100%

80%

10%

0% 0% 0%

3 WPV

AGID(positive rate)Vaccinated group

AGID(positive rate)Control

0 WPV

1 WPV

2 WPV

3 WPV

Vaccinated group

SN titer(GMT)

Control

891

208

1,663

3,104

37141

676

9

Egg

pro

du

ctio

n

NS farm

Ab

no

rmal eg

g

Age (weeks)16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41

120%

100%

80%

60%

40%

20%

0%

4.5%

4.0%

3.5%

3.0%

2.5%

2.0%

1.5%

1.0%

0.5%

0.0%

Egg production (vaccinated)

Abnormal eggs (vaccinated)

Egg production (control)

Abnormal eggs (control)

Egg

pro

du

ctio

nKM farm

Ab

no

rmal eg

g

Age (weeks)16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41

120%

100%

80%

60%

40%

20%

0%

4.5%

4.0%

3.5%

3.0%

2.5%

2.0%

1.5%

1.0%

0.5%

0.0%

Egg production (vaccinated)

Abnormal eggs (vaccinated)

Egg production (control)

Abnormal eggs (control)

1200

1000

800

600

400

200

0

Once at 6~8 wks

0 WPV 3 WPV 0 WPV 3 WPV 0 WPV 3 WPV

TwiceOnce at 18~20 wks

PoulShot® S/9R Intervet SG9R

1200

1000

800

600

400

200

0

Once at 6~8 wks

0 WPV 3 WPV 0 WPV 3 WPV 0 WPV 3 WP2V

TwiceOnce at 18~20 wks

Mic

rop

late

ag

glu

tin

atio

n t

iter

PoulShot® S/9R Vaccine N

WPV: Weeks post vaccination WP2V: Weeks post 2nd vaccination


PoulShot® ND-7 PoulShot® Qx ND-7 PoulShot® BNE

PoulShot® ND-7 and PoulShot® Qx ND-7 form high-titer when compared to the control group

PoulShot® ND-7 and PoulShot® Qx ND-7 are containing ≥ 75 PD50 units per dose

During the trial period, the control group was inoculated with IB and ND vaccine (live and killed vaccine) as per the farm’s vaccination program

Three Major Diseases are protected by One Vaccine that provides the Prolonged high-titer

Indication An aid in the control and prevention of Newcastle disease caused by NDV


Recombinant Newcastle disease virus (NDV, rNDV-mF strain, genotype VII) ≥ 108.0EID50

Indication An aid the control and prevention of Newcastle disease and infectious bronchitis infection caused by NDV and IBV


Recombinant Newcastle disease virus (NDV, rNDV-mF strain, genotype VII) Infectious bronchitis virus (IBV, ADL05258 strain)

≥ 108.0EID50

≥ 106.0EID50


- Chicken can be vaccinated from one-day-old onwards.- Administer 0.2ml to the chickens within 10 days of age, 0.5ml to the chickens at least 10 days of age

IndicationAn aid in the control and prevention of infectious bronchitis, Newcastle disease and egg production syndrome caused by IBV, NDV, and EDSV


Infectious bronchitis virus (IBV, M41 strain) Newcastle disease virus (NDV, LaSota strain) Egg drop syndrome virus (EDSV, K11 strain)

≥ 105.9EID50

≥ 108.4EID50

≥ 107.7EID50


Administer 0.5ml intramuscularly not later than 3 week before egg-laying

KILLEDKI

LLED

Control Control

0 WPV 4 WPV 8 WPV 12 WPV 16 WPV 20 WPV 0 WPV 4 WPV 8 WPV 12 WPV 16 WPV 20 WPV5

6

7

8

9

10

5

6

7

8

9

10

11

1

1.5

2

2.5

3

3.5

4

4.5

Neu

tral

izat

ion

ind

ex (

NI)

HI t

iter

(lo

g2)

NDV, rNDV-mF IBV, ADL05258

WPV: Weeks post vaccination WPV: Weeks post vaccination

10

9

8

7

6

5

4

3

2

1

0

HI t

iter

(lo

g2)

IBV EDSVNDV

4 WPV0 WPV 8 WPV 16 WPV 20 WPV12 WPV

Poultry Vaccines18

PoulShot® 3BN

Three different types of IBV are protected by One Vaccine that provides the Prolonged high-titer

Indication An aid in the control and prevention of Newcastle disease and infectious bronchitis caused by NDV and IBV


Infectious bronchitis virus (IBV, M41 strain, Respiratory type)Infectious bronchitis virus (IBV, KM91 strain, Nephropathogenic type)Infectious bronchitis virus (IBV, ADL05258 strain, Nephropathogenic type)Newcastle disease virus (NDV, LaSota strain)

≥ 105.6EID50

≥ 106.3EID50

≥ 106.3EID50

≥ 108.2EID50


Administer 0.5ml intramuscularly-1st vaccination: 8~12 weeks of age-2nd vaccination: not later than 3 weeks before egg-laying

KILLED

PoulShot® 3BN protects against Nephropathogenic and Respiratory type of IBV100% Protection against highly pathogenic NDV

Six-week-old SPF chickens were inoculated twice at two-week intervals and challenged with three IBV serotypes WPV: Weeks post vaccination

18

16

14

12

10

8

6

4

2

0

100%

90%

80%

70%

60%

50%

40%

30%

20%

10%

0%

9

8

7

6

5

4

3

2

1

0

100%

90%

80%

70%

60%

50%

40%

30%

20%

10%

0%

35

30

25

20

15

10

5

0

100%

90%

80%

70%

60%

50%

40%

30%

20%

10%

0%

SN t

iter

Protectio

n rate

16 87.5%

75%

100%

8 87.5%

25%

100%

32

25%

100%100%

3BN inoculated Control

Protection test (M41) Protection test (KM91) Protection test (QX-like)100% 88% 100%


PoulShot® ING-Plus

PoulShot® ING-Plus provides stable and high potency level for the four major strains

Indication An aid the control and prevention of Newcastle disease, infectious bronchitis and infectious bursal disease caused by NDV, IBV and IBDV


Infectious bronchitis virus (IBV, M41 strain)Infectious bronchitis virus (IBV, KM91 strain) Newcastle disease virus (NDV, LaSota strain) Infectious bursal disease virus (IBDV, CAG strain)

≥ 105.8EID50

≥ 106.1EID50

≥ 108.4EID50

≥ 106.4TCID50

Administration and dosage Administer 0.5ml intramuscularly not later than 3 week before egg-laying

KILL

ED

10

9

8

7

6

5

4

3

2

1

0

1,500

1,350

1,200

1,050

900

750

600

450

300

150

0

Vaccinated group Control group

10

9

8

7

6

5

4

3

2

1

0

1,500

1,350

1,200

1,050

900

750

600

450

300

150

0IBV, M41

strainControl

IBV, M41strain

ControlIBV, KM91

strain

ControlND

ControlIBD

SN titerH

I tit

er

HI t

iter

(lo

g2) SN

titer

IBV, KM91 strain

ND IBD

O WPV 3 WPV 40 WPV

4.3

8.0 8.1

6.2

4.4

5.7

8.58.8

40

1,290

1,448

7.1

IBV, M41

4.3

8.0

7.17.1

IBV, KM91

8.1

6.2

4.4

NDV

5.7

8.58.8

IBDV

40

1,290

1,448

0 WPV 3 WPV 40 WPV

KILLED

PoulShot® Qx Flu-5

IndicationAn aid in the control and prevention of Newcastle disease, infectious bronchitis, egg drop syndrome and low pathogenic avian influenza infection caused by NDV, IBV, EDSV and AIV


Infectious bronchitis virus (IBV, ADL05258 strain) Infectious bronchitis virus (IBV, KM91 strain) Newcastle disease virus (NDV, LaSota strain) Egg drop syndrome virus (EDSV, K11 strain) Avian influenza virus (AIV, H9N2)

≥ 106.0EID50

≥ 106.0EID50

≥ 108.0EID50

≥ 105.5EID50

≥ 108.0EID50


Administer 0.5ml intramuscularly-1st vaccination: 8~12 weeks of age-2nd vaccination: 14~18 weeks of age

Only one vaccine can control the major diseases at a time

Group Before vaccination 3 weeks post 2nd vaccination Control

NDV <1 8.2 ± 0.63* <1

EDSV <1 10.7 ± 0.82 <1

AIV <1 7.9 ± 0.74 <1

IBV, KM91 strain NT** 2.6 <1

IBV, ADL05258 strain NT 2.7 <1

* Average HI titer ± standard deviation** Not tested

Poultry Vaccines20 Global Bio Leader - CAVAC 21

PoulShot® Adeno

PoulShot® Adeno protects from the clinical signs and gross lesion against the challenge

Indication An aid in the control and prevention of fowl adenovirus infection caused by FAdV

Composition and quantity Fowl adenovirus type 4 (FAdV-4, K4 strain) ≥ 107.0TCID50


Administer 0.5ml intramuscularly from 6 weeks old to 4 weeks before egg-laying in breeder and layer

KILL

ED

0

2

4

6

8

10

SN t

iter

(lo

g2)

0 WPV 4 WPC 8 WPC 12 WPC 16 WPC 20 WPC

7.2

00

1

2

3

4

5

6

7

8

SN t

iter

(lo

g2)

0 010

0 0

80 80

100 100 100

010%20%30%40%50%60%70%80%90%100%

Clin

cal s

igns

Mor

talit

y

Hepa

titis

Hydr

oper

icar

dium

Viru

s det

ectio

n

Clin

cal s

igns

Mor

talit

y

Hepa

titis

Hydr

oper

icar

dium

Viru

s det

ectio

n

Vaccinated/Challenged Challenged-only

Para

meter

Challenged-onlyVaccineate/Challenged

Vaccinated Control

Stable and Durable Immunity

0

2

4

6

8

10

HI t

iter

(lo

g2)

NDV EDSV AIV

Neu

tral

izat

ion

In

dex

(N

I)

0

0.5

1

1.5

2

2.5

3

3.5

4

4.5

5

IBV, KM91 strain IBV, ADL05258 strain

13 WP2V5 WP2V1 WP2V4 WP1V0 WP1V 9 WP2V13 WP2V5 WP2V1 WP2V4 WP1V0 WP1V 9 WP2V

WP1V: Weeks post 1st vaccinationWP2V: Weeks post 2nd vaccination

0

2

4

6

8

10

SN t

iter

(lo

g2)

0 WPV 4 WPC 8 WPC 12 WPC 16 WPC 20 WPC

7.2

00

1

2

3

4

5

6

7

8

SN t

iter

(lo

g2)

0 010

0 0

80 80

100 100 100

010%20%30%40%50%60%70%80%90%100%

Clin

cal s

igns

Mor

talit

y

Hepa

titis

Hydr

oper

icar

dium

Viru

s det

ectio

n

Clin

cal s

igns

Mor

talit

y

Hepa

titis

Hydr

oper

icar

dium

Viru

s det

ectio

n

Vaccinated/Challenged Challenged-only

Para

meter

Challenged-onlyVaccineate/Challenged

Vaccinated Control

WPV: Weeks post vaccination WPC: Weeks post challenge

KILLED

PoulShot® Flu H9N2+ND

Induction of Rapid, High and Uniform Antibodies in a Single Vaccination

100% Defense against NDV challenge

PoulShot® Flu H9N2+ND has been sold in Korea more than 12 years!

PoulShot® Flu H9N2+ND has already been registered in Kuwait, Jordan, Iraq, etc.

Indication An aid in the control and prevention of low pathogenic avian influenza infection and Newcastle disease caused by AIV and NDV


Avian influenza virus (AIV, H9N2) Newcastle disease virus (NDV, LaSota strain)

≥ 109.5EID50

≥ 109.5EID50


- Chicken can be vaccinated from one-day-old onwards- Administer 0.2ml to the chickens within 10 days of age, 0.5ml to the chickens at least 10 days of age

Poultry Vaccines22 Poultry Vaccines 23

0 WPV 0 WPV3 WPV 3 WPV

AIV

4

0

1

2

3

5

6

7

8

9

HI t

iter

(lo

g2)

NDV

Flu H9N2+ND 01 Flu H9N2+ND 02 Flu H9N2+ND 03

Tailor-made AI+ND vaccine for Middle East

PoulShot®

Flu H9 ME+ND7

WPV: Weeks post vaccination

Poultry Vaccines24

Application and Cautions of Poultry Vaccines

APPLICATION AND CAUTIONS OF POULTRY VACCINES

EYE DROP

Following the instructions, dilute the vaccine with a diluent and administer single drop. Gently grab the chicken by head for a good position and drop the vaccines onto the eye that should be absorbing the drop at all for sure (make sure the chicken blinks a few time). If the vaccine is absorbed properly, color of the tongue shall be changed and if not, try it again.

DRINKING WATER

The vaccine should be dissolved in drinking water (20~24℃), and then supply the vaccine after restricting water supply for 2 hours at least. In hot weather, deal with a larger amount of water. For better effect, add skim milk powder as a stabilizer by 0.2%. Stop using antibiotics and disinfectant in order not to disturb any effect of the vaccines. Please make sure that the vaccine is absorbed properly. For hygiene reasons, always wear gloves.


Poultry Vaccines

Poultry Vaccines26 Global Bio Leader - CAVAC 27

Anatomical structure and Scab formation Anatomical structure of wing 4 days after vaccination 11 days after vaccination

Application and Cautions of Poultry Vaccines

SPRAY SUBCUTANEOUS INJECTION

WING WEB PUNCTURE

Vaccines are diluted with distilled water or clean water and administered by spraying from height of 50cm in order to administer in the eye and nasal cavity. The droplet size of spray should follow the administrations for use of each vaccine. The droplet size is generally 80~150µm and droplet size and spray method can be changed depending on age and construction of the farm. Before the vaccination, minimize ventilation if possible and dim the lights as low as possible to keep the chickens calm during the vaccination.

Preheat the vaccine that stored in the refrigerator over room temperature before use. Grasp the chicken by hoisting the skin with fingers to create a pocket between neck muscles and skin. Insert the needle at a 90˚ angle into the pocket of skin you made. Make sure that all of the vaccine gets injected and that the needle does not come out of the other side of the skin fold. Avoid injecting vaccine into the neck muscles, intradermaly or too close to the head of chicken. If you inject the vaccine correctly, you should notice a small bubble forming in the vaccination site.

Pull the chicken’s wing, and then the vaccine is put on the puncture niddle to inoculate the center of wing’s arachnoid triangle. Chicken’s vein, bones, wing nerve, and any other part of the body should be avoided. If you accidentally hurt the blood vessel, please do hemostasis and administrate it correctly. After 7~10 days of vaccination, check whether the scab is generated at the inoculation site.

INTRAMUSCULAR INJECTION

Inject vaccine following the administration for use and make sure the vaccine goes into the bird’s muscle. In the breast injection (left), the needle should be directed caudally at a 45˚ angle to the body. This will help avoid injecting the vaccine into the abdominal cavity or liver. When using the leg muscle for vaccination (right), the injection site should be made in the lateral side of the gastrocnemius muscle. Avoid major vessels, nerve, joints and the bone. After vaccination, please check failure of vaccination.

Spray

SprayVaccine

Distilled or clean water Dissolve the

vaccineCheck the

droplet size


COMPANIONANIMAL

VACCINES

CaniShot® DHPPLComposition CaniShot® DHPP

Canine distemper virus (CDV, Onderstepoort strain) Canine adenovirus type 2 (CAV-2, Manhattan strain) Canine parvovirus (CPV, 780916-LP strain)Canine parainfluenza virus (CPIV, D008 strain) CaniShot® LeptoLeptospira canicolaLeptospira icterohaemorhhage

30%10%20%20%

0.5ml0.5ml

Indication An aid in the control and prevention of canine distemper, infectious canine hepatitis, parvovirus infection, infectious tracheobronchitis, and leptospirosis

Packaging unit DHPP-1 dose × 10, Lepto-1 dose × 10

CaniShot® RV-KIndication An aid in the control and prevention of rabies virus infection in dogs, cats, and cow

Packaging unit 1 dose × 10

Composition Rabies virus (RV, Pasteur strain) ≥107.0FAID50

CaniShot® CV Indication An aid in the control and prevention of coronavirus infection

Composition Canine coronavirus (CCV, K378 strain)


≥106.0TCID50

CaniShot® PCIndication An aid in the control and prevention of parvovirus and coronavirus infection


Composition Canine parvovirus (CPV, 780916-LP strain) Canine coronavirus (CCV, K378 strain)

≥105.0TCID50

≥104.0TCID50

CaniShot® K5Indication An aid in the control and prevention of canine distemper, infectious canine hepatitis,

parvovirus infection, and infectious tracheobronchitis


Composition Canine distemper virus (CDV, Rockborn strain) Canine adenovirus type 2 (CAV-2, Manhattan strain) Canine parvovirus (CPV, 780916-LP strain) Canine parainfluenza virus (CPIV, D008 strain)

≥103.5TCID50

≥103.0TCID50

≥105.0TCID50

≥104.0TCID50

Product list

FeliShot® PHC An aid in the control and prevention of feline panleukopenia, feline viral rhinotracheitis and feline calicivirus infection in cats

Feline Panleukopenia virus (FPV, CU4 strain)Feline Herpesvirus (FHV, FVR-Goldstein strain)Feline Calicivirus (FCV, FCV-255 strain)

1 dose × 10

≥ 104.8TCID50

≥ 106.2TCID50

≥ 106.2TCID50

Indication

Composition

Packaging unit

RabbiShot® VHD Plus

An aid in the control and prevention of rabbit hemorrhagic disease in rabbits

Rabbit hemorhhagic diease virus VP60 protein

10 doses / 10ml

≥ 5,000 HAU

Indication

Composition

Packaging unit

Vaccination program

General vaccination program

Rabies vaccine program

Enforced program to prevent Parvovirus

PHC

8 weeks

PHC

14 weeks

PHC

11 weeks Annual booster vaccination

VHD Plus

2 months

VHD Plus

4 months Annual booster vaccination

KC-Plus

5 weeks

KC-Plus

7 weeks

DHPPLorK5

6 weeks

DHPPLorK5

8 weeks

DHPPLorK5

10 weeks

DHPPLorK5

12 weeks

Annual booster

vaccination

DHPPLorK5

PC

4 weeks

PC

8 weeks

DHPPLorK5

6 weeks

DHPPLorK5

10 weeks

DHPPLorK5

12 weeks

At the age older than 3 months

First

RV-K

Annual booster vaccination

Companion Animal Vaccines30 Global Bio Leader - CAVAC 31

Product list

CaniShot® KC-Plus An aid in the control and prevention of Kennel cough

Bordetella bronchiseptica (S-55 strain) Canine parainfluenza virus (CPIV, D008 strain)

1 dose × 10

≥ 2.0X108.0CFU≥ 104.0HAD50

Indication

Composition

Packaging unit

BOVINE VACCINES


Product list

BoviShot® EphemerIndication

Composition

Packaging unit

An aid in the control and prevention of bovine ephemeral fever caused by BEFV

Bovine ephemeral fever virus (BEFV, BG strain)

5 doses / 10ml

≥ 103.0TCID50

BoviShot® RIDIndication An aid in the control and prevention of infectious bovine rhinotracheitis, bovine viral

diarrhea, and bovine parainfluenza virus infection caused by BHV-1, BVDV and BPIV-3

Packaging unit 2 doses / 10ml

Composition Bovine herpesvirus type 1 Bovine viral diarrhea virus Bovine parainfluenza virus type 3

30%30%30%

BoviShot® ROCOIndication

Composition

Packaging unit

An aid in the control and prevention of bovine rotavirus infection and bovine coronavirus caused by BRV and BCV

Bovine rotavirus (678 strain) Bovine rotavirus (P44 strain) Bovine coronavirus (BC94 strain)

1 dose / 2ml

≥ 105.0TCID50

≥ 105.0TCID50

≥ 105.0TCID50

Indication

Composition

Packaging unit

An aid in the control and prevention of bruceollosis caused by Brucella abortus.

Brucella abortus (RB51 strain)

10 doses / 10ml

≥ 4X109.0CFUBoviShot® Brucel

BoviShot® Pneumoguard 4

Indication

Composition

Packaging unit

An aid in the control and prevention of respiratory disease caused by Pasteurella multocida and Mannheimia haemolytica

Pasteurella multocida type A bacterin Pasteurella multocida type A outer membrane proteinMannheimia haemolytica type A bacterin Mannheimia haemolytica type A leukotoxoid

1 dose / 2ml

≥ 2X109.0CFU200µg/ml≥ 2X109.0CFU10µg/ml

BoviShot® EC-P Indication

Packaging unit

An aid in the control and prevention of colibacillosis caused by Escherichia coli

1 dose / 2ml

Composition E.coli pili (K99, F41) 40%

BoviShot® AkabaneAn aid in the control and prevention of abortions, stillbirths and congenital defects caused by Akabane virus

Akabane virus

3 doses / 3ml

50%

Indication

Composition

Packaging unit

Product list

BoviShot® Anth-LegAn aid in the control and prevention of anthrax and blackleg caused by Bacillus anthracis and Clostridium chauvoei

Indication

10 doses / 20mlPackaging unit

Bacillus arthracis Clostridium chauvoei

47.5 ~ 48.5%47.5 ~ 48.5%

Composition

Bovine Vaccines34

ROCOEC-P

6 weeks

ROCOEC-P

4 weeks Farrowing

Cow

Farrowing

ROCOAdminister 4ml (2 doses)

by oral route before giving colostrum

EphemerRID

AkabaneVaccination twice with

2~4 weeks interval

4 monthsCalf

RID

September

Akabane RID

Anth-Leg

MarchSeasonal vaccine

Global NETWORKThe world is our business place and the future is our market.The world is our business place and the future is our market.On the road to the world-class, CAVAC goes hand in hand with On the road to the world-class, CAVAC goes hand in hand with global families from more than 20 countries.global families from more than 20 countries.


choong ang vaccine laboratories co., ltd

Documents